Ceribell Inc., a medical technology company specializing in neurological conditions, reported its financial results for the first quarter of 2025. The company achieved total revenue of $20.5 million, marking a 42% increase from $14.4 million in the same period of 2024. This growth was attributed to increased commercial traction and adoption by new accounts. However, Ceribell reported a net loss of $12.8 million for the first quarter of 2025, compared to a net loss of $8.5 million in the corresponding period of the previous year. Significant operational milestones included receiving U.S. FDA 510(k) clearance for an expanded indication of their Clarity™ algorithm, which is now the first seizure detection algorithm indicated for patients aged 1 and older. Additionally, Ceribell became the first medical device company to secure FedRAMP High authorization from the U.S. federal government. The company ended the quarter with 558 total active accounts and achieved a gross margin of 88%. Looking forward, Ceribell has raised its revenue guidance for the full year 2025 to between $83 million and $87 million, representing a projected growth of approximately 27% to 33% over the previous year's revenue.